RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
RedHill Biopharma (RDHL) Tops Q3 EPS by 41c
November 19, 2019 7:05 AM ESTRedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of $0.03, $0.41 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.4 million versus the consensus estimate of $1.77 million.
Financial highlights for the quarter ended September 30, 2019:
Net Revenues of $1.4 million in the third quarter of 2019, compared to $1.6 million in the second quarter of 2019. Gross Profit of $0.8 million in the third quarter of 2019, compared to $1.1 million in the second quarter of 2019. Research and Development Expenses of $2.8 million in the third quarter of 2019, compared to $7.0 million in the second quarter of 2019.... More